Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005-2019.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 03 07 2020
accepted: 10 09 2020
pubmed: 19 9 2020
medline: 5 8 2021
entrez: 18 9 2020
Statut: ppublish

Résumé

To assess the incidence, clinical, microbiological features and outcome of invasive Streptococcus agalactiae (GBS) infections in non-pregnant adults in three tertiary hospitals of the Brussels-Capital Region. All bacterial cultures positive for GBS, from 2005 to 2019 from 3 hospitals of the Brussels-Capital Region, were extracted, and only cases of invasive diseases were included. Medical files were retrospectively retrieved for risk factors, clinical manifestations and outcome and also antibiotic-susceptibility testing and GBS serotypes. Incidence rates were calculated based on the hospitals catchment populations. A total of 337 cases of GBS-invasive infections were included. The incidence of invasive GBS for the 3 hospitals increased from 3.7 to 8.2 cases per 100.000 inhabitants between 2009 and 2018 (p = 0.04). The most frequently identified risk factors were diabetes (36.8%), obesity (35.0%), cancer (21.7%), renal disease (20.8%), and advanced age (≥ 65 years; 47.2%). Isolated bacteremia (22%), osteoarticular infection (21.4%), abscesses (13.9%), and skin and soft tissue infections (18.4%) were the most frequent manifestations. Intensive care unit admission was required in 21.7% and overall mortality was 9.4%. All strains remained susceptible to penicillin over the years. Up to 20% of strains were resistant to clindamycin. Serotypes Ia, Ib, II, III, IV, and V represented 96.8% of the available serotypes (60/62). As reported in several countries, invasive GBS disease in non-pregnant adults represents an increasing burden, particularly among diabetic, obese, and elderly patients. Almost all serotypes identified are included in the upcoming hexavalent GBS conjugate vaccine.

Identifiants

pubmed: 32944894
doi: 10.1007/s10096-020-04041-0
pii: 10.1007/s10096-020-04041-0
pmc: PMC7498195
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

515-523

Références

Pimentel BAS, Martins CAS, Mendonça JC, Miranda PSD, Sanches GF, Mattos-Guaraldi AL et al (2016) Streptococcus agalactiae infection in cancer patients: a five-year study. Eur J Clin Microbiol Infect Dis 35:927–933. https://doi.org/10.1007/s10096-016-2617-9
doi: 10.1007/s10096-016-2617-9 pubmed: 26993288
Barshak MB (2019) Group B Streptococcus, an A-list pathogen in nonpregnant adults. JAMA Intern Med 179:488. https://doi.org/10.1001/jamainternmed.2018.7296
doi: 10.1001/jamainternmed.2018.7296 pubmed: 30776057
Russell NJ, Seale AC, O’Driscoll M, O’Sullivan C, Bianchi-Jassir F, Gonzalez-Guarin J et al (2017) Maternal colonization with group B streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis 65:S100–S111. https://doi.org/10.1093/cid/cix658
doi: 10.1093/cid/cix658 pubmed: 29117327 pmcid: 5848259
Hasperhoven G, Al-Nasiry S, Bekker V, Villamor E, Kramer B (2020) Universal screening versus risk-based protocols for antibiotic prophylaxis during childbirth to prevent early-onset group B streptococcal disease: a systematic review and meta-analysis. BJOG Int J Obstet Gynaecol 127:680–691. https://doi.org/10.1111/1471-0528.16085
doi: 10.1111/1471-0528.16085
Rantz LA (1940) Suppurative arthritis due to a hemolytic streptococcus of the lancefield group B: a case report. Ann Intern Med 1(13):1744. https://doi.org/10.7326/0003-4819-13-9-1744
Francois Watkins LK, McGee L, Schrag SJ, Beall B, Jain JH, Pondo T et al (2019) Epidemiology of invasive group B Streptococcal infections among nonpregnant adults in the United States, 2008-2016. JAMA Intern Med 179:479. https://doi.org/10.1001/jamainternmed.2018.7269
doi: 10.1001/jamainternmed.2018.7269 pubmed: 30776079 pmcid: 6450309
Björnsdóttir ES, Martins ER, Erlendsdóttir H, Haraldsson G, Melo-Cristino J, Kristinsson KG et al (2016) Changing epidemiology of group B streptococcal infections among adults in Iceland: 1975–2014. Clin Microbiol Infect 22:379.e9–379.e16. https://doi.org/10.1016/j.cmi.2015.11.020
doi: 10.1016/j.cmi.2015.11.020
Martins ER, Melo-Cristino J, Ramirez M (2012) The Portuguese group for the study of Streptococcal infections. Dominance of serotype Ia among group B streptococci causing invasive infections in nonpregnant adults in Portugal. J Clin Microbiol 50:1219–1227. https://doi.org/10.1128/JCM.05488-11
doi: 10.1128/JCM.05488-11 pubmed: 22219307 pmcid: 3318525
Tazi A, Morand PC, Réglier-Poupet H, Dmytruk N, Billoët A, Antona D et al (2011) Invasive group B streptococcal infections in adults, France (2007–2010). Clin Microbiol Infect 17:1587–1589. https://doi.org/10.1111/j.1469-0691.2011.03628.x
doi: 10.1111/j.1469-0691.2011.03628.x pubmed: 21883671
Collin SM, Shetty N, Lamagni T (2020) Invasive group B streptococcus infections in adults, England, 2015–2016. Emerg Infect Dis 26:1174–1181. https://doi.org/10.3201/eid2606.191141
doi: 10.3201/eid2606.191141 pubmed: 32441619 pmcid: 7258460
High KP, Edwards MS, Baker CJ (2005) Group B streptococcal infections in elderly adults. Clin Infect Dis 41:839–847. https://doi.org/10.1086/432804
doi: 10.1086/432804
Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N et al (2008) First Molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 52:2890–2897. https://doi.org/10.1128/AAC.00185-08
doi: 10.1128/AAC.00185-08 pubmed: 18490507 pmcid: 2493108
McGee L, Chochua S, Li Z, Mathis S, Rivers J, Metcalf B et al (2020) Multistate, population-based distributions of candidate vaccine targets, clonal complexes, and resistance features of invasive group B streptococci within the United States, 2015–2017. Clin Infect Dis 15:ciaa151. https://doi.org/10.1093/cid/ciaa151
doi: 10.1093/cid/ciaa151
Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM et al (2008) Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008:1–5. https://doi.org/10.1155/2008/727505
doi: 10.1155/2008/727505
Sacheli R, Melin P (2016) Rapport d’activités du Centre National de Référence du Streptococcus agalactiae
Buurman ET, Timofeyeva Y, Gu J, Kim J, Kodali S, Liu Y et al (2019) A Novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal group B streptococcal infections by maternal immunization. J Infect Dis 220:105–115. https://doi.org/10.1093/infdis/jiz062
doi: 10.1093/infdis/jiz062 pubmed: 30778554 pmcid: 6548902
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381. https://doi.org/10.1016/j.jbi.2008.08.010
doi: 10.1016/j.jbi.2008.08.010
Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251. https://doi.org/10.1016/0895-4356(94)90129-5
doi: 10.1016/0895-4356(94)90129-5 pubmed: 7722560
Melin, P. Evaluation externe de la qualité des analyses en biologie clinique. Rapport de microbiologie enquête 02/2005. Partim Streptococcus agalactiae [Internet]. 2005 [cited 2020 7];doi: https://www.wiv-isp.be/QML/activities/external_quality/rapports/_down/microbiologie/2005/05-2F-MICROBIO.pdf
Poyart C, Tazi A, Reglier-Poupet H, Billoet A, Tavares N, Raymond J et al (2007) Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. J Clin Microbiol 45:1985–1988. https://doi.org/10.1128/JCM.00159-07
doi: 10.1128/JCM.00159-07 pubmed: 17376884 pmcid: 1933079
Kong F, Lambertsen LM, Slotved H-C, Ko D, Wang H, Gilbert GL (2008) Use of phenotypic and molecular serotype identification methods to characterize previously nonserotypeable group B streptococci. J Clin Microbiol 46:2745–2750. https://doi.org/10.1128/JCM.00189-08
doi: 10.1128/JCM.00189-08 pubmed: 18562579 pmcid: 2519501
RHM: Parts de marché des hôpitaux par commune de résidence des patients et classe d’âge [Internet]. [cited 2020 12];doi: https://www.health.belgium.be/fr/rhm-parts-de-marche-des-hopitaux-par-commune-de-residence-des-patients-et-classe-dage
Jump RLP, Wilson BM, Baechle D, Briggs JM, Banks RE, Song S et al (2019) Risk factors and mortality rates associated with invasive group B Streptococcus infections among patients in the US Veterans Health Administration. JAMA Netw Open 27(2):e1918324. https://doi.org/10.1001/jamanetworkopen.2019.18324
doi: 10.1001/jamanetworkopen.2019.18324
Lamagni TL, Keshishian C, Efstratiou A, Guy R, Henderson KL, Broughton K et al (2013) Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991–2010. Clin Infect Dis 57:682–688. https://doi.org/10.1093/cid/cit337
doi: 10.1093/cid/cit337 pubmed: 23845950
Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K et al (2009) Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007. Clin Infect Dis 49:85–92. https://doi.org/10.1086/599369
doi: 10.1086/599369 pubmed: 19480572
Sacheli R, Meex C, Melin P, Descy J, Huynen P, Hayette M-P. Surveillance of group B streptococcus (GBS) strains isolated from invasive diseases among adults in Belgium: Bacteriological and clinical characteristics. [Internet]. 2018 [cited 2020 7];doi: http://hdl.handle.net/2268/223202
Healthy Belgium. Obesity prevalence in Belgium [Internet]. [cited 2020 14];doi: https://www.belgiqueenbonnesante.be/fr/etat-de-sante/determinants-de-sante/statut-ponderal
Healthy Belgium. Diabetes prevalence in Belgium [Internet]. [cited 2020 14]; https://www.healthybelgium.be/en/health-status/non-communicable-diseases/diabetes
Centers for Disease Control and Prevention. 2016. Active bacterial core surveillance report, emerging infections program network, Streptococcus pneumoniae, 2016. 2018 20; https://www.cdc.gov/abcs/reports-findings/survreports/spneu16.pdf
Santé Publique France. Bilan annuel 2018: Impact de la vaccination par le vaccin pneumococcique conjugué 13-valent (VPC13) sur l’incidence des infections invasives à pneumocoques. Données du réseau Epibac et du CNR des pneumocoques (réseau CNRP-ORP) [Internet]. [cited 2020 12]; https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infections-a-pneumocoque/donnees/#tabs
Cardoso T, Almeida M, Friedman ND, Aragão I, Costa-Pereira A, Sarmento AE et al (2014) Classification of healthcare-associated infection: a systematic review 10 years after the first proposal. BMC Med 12:40. https://doi.org/10.1186/1741-7015-12-40
doi: 10.1186/1741-7015-12-40 pubmed: 24597462 pmcid: 4016612
Collin SM, Lamb P, Jauneikaite E, Le Doare K, Creti R, Berardi A et al (2019) Hospital clusters of invasive group B streptococcal disease: a systematic review. J Infect 79:521–527. https://doi.org/10.1016/j.jinf.2019.11.008
Heath PT, Culley FJ, Jones CE, Kampmann B, Le Doare K, Nunes MC et al (2017) Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. Lancet Infect Dis 17:e223–e234. https://doi.org/10.1016/S1473-3099(17)30232-3
doi: 10.1016/S1473-3099(17)30232-3 pubmed: 28433702
Dauby N (2019) Vaccination for the prevention of group B Streptococcus infection in nonpregnant adults. JAMA Intern Med 179:998. https://doi.org/10.1001/jamainternmed.2019.1590
doi: 10.1001/jamainternmed.2019.1590 pubmed: 31260012

Auteurs

Elena Graux (E)

Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles (ULB), 322, rue Haute, 1000, Bruxelles, Belgium.

Maya Hites (M)

Clinic of Infectious Diseases, Cliniques Universitaires de Bruxelles Erasme, Bruxelles, Belgium.

Delphine Martiny (D)

Department of Microbiology, Laboratoire des Hôpitaux Universitaires de Bruxelles - Universitaire Laboratorium Brussel (LHUB-ULB), Bruxelles, Belgium.
Faculté de Médecine et Pharmacie, Université de Mons (UMONS), Mons, Belgium.

Evelyne Maillart (E)

Department of Infectious Diseases, CHU Brugmann, Bruxelles, Belgium.

Marc Delforge (M)

Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles (ULB), 322, rue Haute, 1000, Bruxelles, Belgium.

Pierrette Melin (P)

Clinical Microbiology, CHU Liège, National Reference Centre Streptococcus agalactiae, CIRM, Liège, Belgium.

Nicolas Dauby (N)

Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles (ULB), 322, rue Haute, 1000, Bruxelles, Belgium. Nicolas_DAUBY@stpierre-bru.be.
Centre for Environmental Health and Occupational Health, School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium. Nicolas_DAUBY@stpierre-bru.be.
Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Brussels, Belgium. Nicolas_DAUBY@stpierre-bru.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH